Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

MLA

Shatsky, Rebecca A., et al. “Datopotamab-Deruxtecan plus Durvalumab in Early-Stage Breast Cancer: The Sequential Multiple Assignment Randomized I-SPY2.2 Phase 2 Trial.” Nature Medicine, Sept. 2024. EBSCOhost, https://doi.org/10.1038/s41591-024-03267-1.

APA

Shatsky, R. A., Trivedi, M. S., Yau, C., Nanda, R., Rugo, H. S., Davidian, M., Tsiatis, B., Wallace, A. M., Chien, A. J., Stringer-Reasor, E., Boughey, J. C., Omene, C., Rozenblit, M., Kalinsky, K., Elias, A. D., Vaklavas, C., Beckwith, H., Williams, N., Arora, M., … Esserman, L. J. (2024). Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03267-1

Chicago

Shatsky, Rebecca A, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Marie Davidian, Butch Tsiatis, et al. 2024. “Datopotamab-Deruxtecan plus Durvalumab in Early-Stage Breast Cancer: The Sequential Multiple Assignment Randomized I-SPY2.2 Phase 2 Trial.” Nature Medicine, September. doi:10.1038/s41591-024-03267-1.